Cipla Ltd.

Cipla has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (NDA) submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’ on February 19, 2025.

Nilotinib is an oncology category product in capsule form for oral consumption and is used for treatment of philadelphia chromosome positive chronic myeloid leukemia (CML). The product is expected to be launched in FY 2025-26 in the United States of America.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.